New Stem Cell-Derived Islet Therapy Improves Blood Sugar Control in All Treated Patients, with Three of Six Achieving Insulin Independence in Phase 1/2 Study; “The Results Are Truly Remarkable,” Researcher Comments

Cross-section of Islets of Langerhans where insulin-secreting beta cells are found in normal individuals.

Six adults with type 1 diabetes (T1D) treated with stem cell-derived islet cells (VX-880) have shown improved blood sugar control with three participants achieving insulin independence, according to new research being presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Hamburg (2-6 Oct). All patients treated with VX-880 have demonstrated improved glycemic control, as evidenced by elimination of severe hypoglycemia (low blood sugar), improvements in HbA1c (a measure of long-term sugar levels), and the amount of time their blood glucose levels were within the recommended range, as well as a reduction or elimination of their externally administered insulin needs.

Login Or Register To Read Full Story